N/A N=40 Randomized Treatment

Relaxation Treatment for Anxiety in Adults Aged 60 or Older

Anxiety Disorders

Bottom Line

View on ClinicalTrials.gov: NCT02429778 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2020

Primary outcome: Primary: Change in Anxiety Symptoms — 17.95; 26.2 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Diaphragmatic Breathing (Behavioral); Progressive Muscle Relaxation (Behavioral)
Age: Adult, Older Adult · 60+ yrs
Sex: All
Sponsor: Palo Alto Veterans Institute for Research
Primary completion: Jun 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Anxiety Symptoms	17.95; 26.2	—
PRIMARY Change in Activity Engagement	49.97; 50.15; 54.97; 48.23	—
SECONDARY Change in Depressive Symptoms	8.40; 6.80; 5.71; 8.6	—
SECONDARY Change in Somatic Symptoms	9.50; 8.80; 6.64; 10.30	—

Summary

The PI developed a self-directed program to treat late-life anxiety called Breathing, Relaxation, and Education for Anxiety Treatment in the Home Environment (BREATHE). This program consists of weekly video lessons that participants watch on digital video disc (DVD) along with weekly telephone check-ins. In BREATHE participants will learn two behavioral interventions: diaphragmatic breathing and progressive muscle relaxation (PMR). The purpose of the study is to examine whether the self-directed BREATHE program is superior to a wait list control in reducing anxiety in older adults with anxiety disorders. For those assigned to wait list control, they will be offered opportunity to participate in BREATHE treatment after 8 weeks of wait list.

Eligibility Criteria

Inclusion Criteria

Participants have a diagnosis of an anxiety disorder, specifically, Generalized Anxiety Disorder, Panic Disorder, Agoraphobia, Social Anxiety Disorder or Anxiety Disorder Unspecified/Other Specified).
Participants speak English.

Exclusion Criteria

Diagnosis of Dementia
Probable presence of significant cognitive impairment according to a brief cognitive screen
Serious mental illness (schizophrenia, psychosis, bipolar disorder)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02429778). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.